$35
Qui Tam / Healthcare Fraud / Off-Label Marketing
Case results reflect publicly available information reported by the listed law firms. They are not results obtained by ThatCarHitMe.com. Every case is unique and must be evaluated on its own facts. Prior results do not guarantee a similar outcome. The results shown are not necessarily representative of all results obtained by these firms. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers.
Case Details
Qui tam lawsuit alleging that Novartis Pharmaceuticals Corporation pushed off-label uses of its eczema medication Elidel for patients under two years old, despite studies indicating potential risks of skin cancer and non-Hodgkin’s lymphoma. The company also allegedly provided kickbacks to doctors. The whistleblower, Donald Galmines, a former Novartis sales rep, pursued the case under the False Claims Act, resulting in a settlement of over $35 million.
Additional Notes
Whistleblower Donald Galmines, a former Novartis sales rep, received about 29% of the recovery. The government chose not to intervene, but the whistleblower proceeded with the case.